Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29476468 | 1.00 | CDC25B (0.35) | CDC25B | |
| SCHEMBL23649908 | 0.74 | CDC25B (0.36) | CDC25B | |
| SCHEMBL2564384 | 0.73 | CDC25B (0.35) | CDC25B | |
| SCHEMBL26512105 | 0.73 | CDC25B (0.33) | CDC25B | |
| SCHEMBL3634375 | 0.73 | — | — | |
| SCHEMBL29362249 | 0.71 | — | — | |
| SCHEMBL5799303 | 0.71 | — | — | |
| SCHEMBL28210860 | 0.70 | TYRO3 (0.33) | — | |
| SCHEMBL422360 | 0.70 | ALDH1A1 (0.41) | — | |
| SCHEMBL2043197 | 0.69 | CDC25B (0.35) | CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108578410-B | Application of octahydro quinazoline-5-one derivative as dengue virus inhibitor | 南方医科大学 | 2020-12-22 | — | — | CN | claimed |
| CN-105130998-A | Preparation method for copanlisib | Suzhou lixin pharmaceutical co ltd | 2015-12-09 | — | — | CN | claimed |
| JP-4808156-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| EP-1663994-A1 | CONDENSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2006-06-07 | — | — | EP | claimed |
| US-20050187217-A1 | Compositions useful as inhibitors of voltage-gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2005-08-25 | — | — | US | claimed |
| WO-2005014558-A1 | CONDENSED PYRAMIDINE COMPOUNDS AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-17 | — | — | WO | claimed |
| EP-0733633-B1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-28 | — | — | EP | claimed |
| EP-1177195-B1 | 1-AMINO TRIAZOLO 4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV | WARNER LAMBERT CO (US) | 2003-03-19 | — | — | EP | claimed |
| JP-2002543199-A | — | — | 2002-12-17 | — | — | JP | claimed |
| CN-1352644-A | I-amino triazolo [4,3-alpha] quinazoline -5-ones and/or -5-thiones inhibiting phosphodiesterase IV | WARNER LAMBERT CO (US) | 2002-06-05 | — | — | CN | claimed |
| EP-1177195-A1 | 1-AMINO TRIAZOLO 4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV | WARNER-LAMBERT COMPANY (US) | 2002-02-06 | — | — | EP | claimed |
| WO-2000066584-B1 | 1-AMINO TRIAZOLO¢4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV | WARNER LAMBERT CO (US) | 2001-02-15 | — | — | WO | claimed |
| WO-2000066584-A1 | 1-AMINO TRIAZOLO¢4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV | WARNER-LAMBERT COMPANY (US) | 2000-11-09 | — | — | WO | claimed |
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | claimed |
| US-20250262167-A1 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2025-08-21 | — | — | US | disclosed |
| US-12377102-B2 | Compounds for the prevention and treatment of medical disorders and uses thereof | GALECTIN SCIENCES, LLC (US) | 2025-08-05 | — | — | US | disclosed |
| US-12162893-B2 | Tricyclic pyridones and pyrimidones | ERASCA, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-4226994-A | BUTANOL SOLVENT, ANTHRANILIC ACID, CYANAMIDE, HYDRAZINE | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-10-07 | — | — | US | disclosed |
| US-4145420-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1979-03-20 | — | — | US | disclosed |
| US-3897434-A | Pyrazolo{8 1,5-c{9 quinazolin-5(6H)-ones | LILLY CO ELI | 1975-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187217-A1 | Compositions useful as inhibitors of voltage-gated ion channels | KCNQ1, KCNN2, KCNH3 | CDC25B 2229/4885 |
| US-12162893-B2 | Tricyclic pyridones and pyrimidones | DHFR, TYMS, TYMP | CDC25B 287/4885 |
| US-12377102-B2 | Compounds for the prevention and treatment of medical disorders and uses thereof | LGALS1, LGALS2, LGALS3 | CDC25B 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.